Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pembrolizumab/vibostolimab - Merck Sharp & Dohme

Next Previous
X
Search
Drug Profile

Pembrolizumab/vibostolimab - Merck Sharp & Dohme

Alternative Names: Coformulation pembrolizumab/vibostolimab - Merck Sharp & Dohme; MK-7684A; Pembrolizumab+vibostolimab; Vibostolimab+pembrolizumab; Vibostolimab/pembrolizumab - Merck Sharp & Dohme

Latest Information Update: 27 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer
  • Phase II Biliary cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Haematological malignancies; Head and neck cancer; Liver cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Triple negative breast cancer; Uterine cancer
  • Phase I/II Bladder cancer; Solid tumours

Most Recent Events

  • 14 Aug 2024 Phase-II clinical trials in Renal cell carcinoma (IV) (Merck Sharp & Dohme pipeline, August 2024)
  • 09 Aug 2024 Merck Sharp & Dohme discontinues a phase III KEYVIBE-008 trial in Small cell lung cancer in Australia, Austria, France, Germany, Lithuania, Poland, Hungary, Finland, Israel, Spain, South Korea, Argentina, Canada, China, Greece, Ireland, Italy, Japan, Mexico, Netherlands, Portugal, Romania, Turkey, United Kingdom and the USA based on the recommendation of an independent Data Monitoring Committee (DMC) (NCT05224141)
  • 25 Jul 2024 Phase-I/II clinical trials in Haematological malignancies (Combination therapy, In adolescents, In children, Second-line therapy or greater, Late-stage disease) in South Korea (IV) (NCT06395090)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top